Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

BACKGROUND This study was designed to determine the safety, tolerability, and pharmacokinetics (PK) of alisertib (MLN8237) in combination with docetaxel and to identify a recommended dose for the combination. METHODS Adults with metastatic cancer were treated on 21‐day cycles with alisertib (10, 20,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2016-08, Vol.122 (16), p.2524-2533
Hauptverfasser:	Graff, Julie N., Higano, Celestia S., Hahn, Noah M., Taylor, Matthew H., Zhang, Bin, Zhou, Xiaofei, Venkatakrishnan, Karthik, Leonard, E. Jane, Sarantopoulos, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over alisertib Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use aurora A kinase Aurora Kinase A - antagonists & inhibitors Azepines - administration & dosage Azepines - pharmacokinetics Biomarkers Drug Administration Schedule Female Humans Male Middle Aged Multimodal Imaging Neoplasm Grading Neoplasm Staging Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - mortality novel antitumor agents pharmacokinetics/pharmacodynamics Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics solid tumors Taxoids - administration & dosage Taxoids - pharmacokinetics Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!